Skip to Content
Merck
All Photos(2)

Key Documents

GF26290313

Platinum

tube, 50mm, outside diameter 2.0mm, inside diameter 1.6mm, wall thickness 0.2mm, as drawn, 99.95%

Synonym(s):

Platinum, PT007250

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
Pt
CAS Number:
Molecular Weight:
195.08
MDL number:
UNSPSC Code:
12141734
PubChem Substance ID:
NACRES:
NA.23

Assay

99.95%

form

tubes

manufacturer/tradename

Goodfellow 262-903-13

resistivity

10.6 μΩ-cm, 20°C

L × wall thickness

50 m × 0.2 mm

O.D. × I.D.

2.0 mm × 1.6 mm

bp

3827 °C (lit.)

mp

1772 °C (lit.)

density

21.45 g/cm3 (lit.)

SMILES string

[Pt]

InChI

1S/Pt

InChI key

BASFCYQUMIYNBI-UHFFFAOYSA-N

General description

For updated SDS information please visit www.goodfellow.com.

Legal Information

Product of Goodfellow

Storage Class Code

13 - Non Combustible Solids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Thorsten Langer et al.
Trends in pharmacological sciences, 34(8), 458-469 (2013-06-19)
Childhood cancer survival rates are now nearly 80% in more developed European countries because of improved therapies and better supportive care. Platinum chemotherapy drugs, such as cisplatin and carboplatin, are the cornerstone of many effective therapeutic protocols for childhood cancer.
Fausto Petrelli et al.
Lung cancer (Amsterdam, Netherlands), 81(3), 337-342 (2013-07-31)
The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. The potential usefulness of platinum-based doublets as rechallenge for second-line chemotherapy has not yet been established.
Himashinie V K Diyabalanage et al.
Cancer letters, 329(1), 1-8 (2012-10-04)
One of the most promising strategies to increase the efficacy of standard chemotherapy drugs is by combining them with low doses of histone deacetylases inhibitors (HDACis). Regarded as chemosensitizers, the addition of well-tolerated doses of HDACis to platinum-based chemotherapeutics has
Hai-Bo Wei et al.
Chinese medical journal, 125(16), 2902-2907 (2012-08-31)
Platinum-based regimens are used as standard first-line chemotherapy in non-small cell lung cancer (NSCLC) patients. To study if pharmacogenetic approach may allow a tailored selection of platinum chemotherapy for advanced NSCLC, we performed a meta-analysis to compare chemosensitivity to platinum
Xiao-yong Shen et al.
PloS one, 8(8), e69553-e69553 (2013-08-14)
X-ray repair cross-complementing protein 3 (XRCC3) is an essential gene involved in the double-strand break repair pathway. Published evidence has shown controversial results about the relationship between XRCC3 Thr241Met polymorphism and clinical outcomes of non-small cell lung cancer (NSCLC) patients

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service